Alnylam PharmaceuticalsvsJohnson & Johnson

ALNY and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

ALNY

Alnylam Pharmaceuticals, Inc.

$148.77

Value $19.7B

+0.62%
ALNY's page

Alnylam Pharmaceuticals (ALNY) has a market value of $19.7B and Johnson & Johnson (JNJ) $652B. Over the last year, with dividends, ALNY moved -67.7% and JNJ +36.7%. Dividend yield: ALNY none, JNJ 1.95%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ALNY$19.7B

    JNJ$652B

    JNJ is 33 times ALNY

  • Revenue, 12 months

    ALNY$5.0B

    JNJ$99.3B

    JNJ is 20 times ALNY

  • Net income, 12 months

    ALNY$2.6B

    JNJ$16.1B

    JNJ is 6.1 times ALNY

  • Operating margin

    ALNY19.5%

    JNJ–

  • ROIC

    ALNY31.8%

    JNJ12.4%

    19.4 points apart

  • P/E

    ALNY–

    JNJ40.5

  • Dividend yield

    ALNY0.0%

    JNJ2.0%

    2.0 points apart

  • 5-year return

    ALNY-17.8%

    JNJ+91.1%

    108.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ALNY-17.8%

JNJ+91.1%

10020020222023202420252026
Returns by period
PeriodALNYWith dividendsJNJWith dividends
1 year since November 19, 2025-67.7%Price -67.7%+36.7%Price +33.7%
3 years since November 20, 2023-10.0%-3.4% a yearPrice -10.0%+95.1%+25.0% a yearPrice +80.6%
5 years since November 19, 2021-17.8%-3.8% a yearPrice -17.8%+91.1%+13.8% a yearPrice +66.2%
10 years since November 21, 2016+215.5%+12.2% a yearPrice +215.5%+206.8%+11.9% a yearPrice +135.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ALNYAlnylam PharmaceuticalsJNJJohnson & Johnson

Valuation

ALNYJNJ
Valuation
Price$148.77$270.71
Market value$19.7B$652B
Enterprise value (EV)–$680B
P/E–40.5
P/E, 5-year median–21.9
P/B5.58.0
EV/EBIT–38.3
Free cash flow yield4.1%3.2%

Results and growth

ALNYJNJ
Results and growth
Revenue, 12 months$5.0B$99.3B
Net income, 12 months$2.6B$16.1B
Free cash flow, 12 months$806M$20.6B
Earnings per share, 12 months$19.98$6.59
Revenue growth, year on year65.2%6.1%
Revenue growth a year, past+49.8%over 5 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

ALNYJNJ
Margins and returns on capital
Gross margin77.4%67.6%
Operating margin19.5%–
Net margin52.8%16.2%
ROIC31.8%12.4%
ROE178.9%19.7%

Balance sheet

ALNYJNJ
Balance sheet
Cash$3.6B$17.2B
Total debt–$44.7B
Net debt / EBITDA–1.1
Interest cover3.3×18.0×

Dividends and buybacks

ALNYJNJ
Dividends and buybacks
Dividend yield–2.0%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ALNY or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Alnylam Pharmaceuticals or Johnson & Johnson?

By market value, Johnson & Johnson ($652B) is about 33.1 times Alnylam Pharmaceuticals ($19.7B), at today's prices.

How did ALNY and JNJ stock do over the last 10 years?

Since November 21, 2016, ALNY's price moved +215.5% and JNJ's +135.4%. With dividends: ALNY +215.5% (+12.2% a year), JNJ +206.8% (+11.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, ALNY or JNJ?

The dividend yield at today's price is none for Alnylam Pharmaceuticals and 1.95% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, Alnylam Pharmaceuticals or Johnson & Johnson?

Over the last twelve months, the net margin was 52.8% for Alnylam Pharmaceuticals and 16.2% for Johnson & Johnson, and the operating margin 19.5% and –. Revenue was $5.0B and $99.3B.

Which is the better investment, Alnylam Pharmaceuticals or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.